| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.LUNGCAN.2016.12.002 |
| P698 | PubMed publication ID | 28213001 |
| P50 | author | Chong-Jen Yu | Q42255080 |
| Wei-Yu Liao | Q57020031 | ||
| P2093 | author name string | Chien-Ying Liu | |
| Gee-Chen Chang | |||
| Meng-Chih Lin | |||
| Yuh-Min Chen | |||
| Te-Chun Hsia | |||
| Chih-Yen Tu | |||
| Meng-Jer Hsieh | |||
| Ying-Huang Tsai | |||
| Tsung-Ying Yang | |||
| Jeng-Sen Tseng | |||
| Kun-Chieh Chen | |||
| Kuo-Hsuan Hsu | |||
| Cheng-Ta Yang | |||
| Wen-Shuo Wu | |||
| Chien-Hua Tseng | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| P304 | page(s) | 58-64 | |
| P577 | publication date | 2016-12-14 | |
| P1433 | published in | Lung Cancer | Q641464 |
| P1476 | title | Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study | |
| P478 | volume | 104 |
| Q41346859 | A novel EGFR-TKI inhibitor (cAMP-H3BO3complex) combined with thermal therapy is a promising strategy to improve lung cancer treatment outcomes |
| Q91328931 | Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study) |
| Q91744738 | CaSR Induces Osteoclast Differentiation and Promotes Bone Metastasis in Lung Adenocarcinoma |
| Q33640472 | Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. |
| Q47681639 | Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment |
| Q33880574 | Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells. |
| Q90719140 | Small molecules, big impact: 20 years of targeted therapy in oncology |
| Q88567528 | The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer |
Search more.